HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Note: This page redirects to the Kimmtrak page, which contains full prescribing information.
20 mcg IV week 1, 30 mcg IV week 2, then 68 mcg IV weekly.
Cytokine Release Syndrome (CRS): Occurs in majority of patients. Skin reactions: Rash common. Elevated liver enzymes. Requires hospitalization/observation for first 3 doses.
CRS (89%), rash (75%), pyrexia (70%), pruritus (61%), fatigue (52%), nausea (42%), chills (38%), hypotension (29%)
Consult the complete prescribing information for a comprehensive list of adverse reactions and their frequencies.
Tebentafusp is an Immune Mobilizing Monoclonal T Cell Receptor Against Cancer (ImmTAC) consisting of a high-affinity T-cell receptor (TCR) domain that targets a gp100 peptide-HLA-A*02:01 complex on melanoma cells, fused to an anti-CD3 antibody fragment that activates T cells. This redirects T cells to kill gp100-expressing uveal melanoma cells regardless of their native TCR specificity.
Half-life: ~8 hrs. Route: IV. Refer to the full prescribing information for complete pharmacokinetic data.
Clinical efficacy and safety data are available in the full prescribing information and referenced publications.
HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. Note: This page redirects to the Kimmtrak page, which contains full prescribing information.
Tebentafusp is an Immune Mobilizing Monoclonal T Cell Receptor Against Cancer (ImmTAC) consisting of a high-affinity T-cell receptor (TCR) domain that targets a gp100 peptide-HLA-A*02:01 complex on melanoma cells, fused to an anti-CD3 antibody fragment that activates T cells. This redirects T cells to kill gp100-expressing uveal melanoma cells regardless of their native TCR specificity.
CRS (89%), rash (75%), pyrexia (70%), pruritus (61%), fatigue (52%), nausea (42%), chills (38%), hypotension (29%)